Zevra Therapeutics (ZVRA) Net Margin (2019 - 2026)

Zevra Therapeutics (ZVRA) has 8 years of Net Margin data on file, last reported at 104.61% in Q1 2026.

• Quarterly Net Margin rose 11980.0% year-over-year to 104.61% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 101.54% (up 32863.0% YoY) and the FY2025 annual result came in at 78.17%, up 52502.0% from the prior year.
• Net Margin climbed to 104.61% in Q1 2026, from 35.6% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 288.66% in Q2 2025 to a low of 1920.29% in Q2 2022.
• A 5-year average of 327.7% and a median of 269.01% in 2024 frame the typical range for Net Margin.
• Annual changes were most pronounced in 2022 — Net Margin sank 183106 bps — and 2023, when it jumped 188991 bps.
• Tracing ZVRA's Net Margin over 5 years: stood at 446.14% in 2022, then soared by 65 bps to 153.96% in 2023, then plunged by 93 bps to 297.53% in 2024, then surged by 112 bps to 35.6% in 2025, then jumped by 194 bps to 104.61% in 2026.
• The last three Net Margin figures came in at 104.61% (Q1 2026), 35.6% (Q4 2025), and 2.09% (Q3 2025), per Business Quant data.